Close Menu

Grants

Additional funding opportunities

Research Funding Opportunities

Tools to Find Funding

Grants Awarded for Health Sciences Research

Title Type $ Amount Activitysort descending Investigator Unit Sponsor Date
A Phase 1 Study of Oral LY3410738 to Patients with Advanced Solid Tumors with IDH1 Mutations Contract $452,432.52 Clinical Trial Rachna Shroff Cancer Center Division Medpace 11/2020
SEER-Lung: A Prospective Blood Sample Collection Study to Develop and Validate a Panel of Protein-based Biomarkers in Patients with Pulmonary Nodules Contract $23,319.00 Clinical Trial Raed Alalawi COM Phx Internal Medicine Seer, Inc. 07/2020
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma Contract $265,397.00 Clinical Trial Montaser Shaheen Cancer Center Division Bristol-Myers Squibb 10/2020
An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor.. Contract $2,247,249.52 Clinical Trial Ricklie Julian Cancer Center Division Bayer Pharmaceutical 04/2021
A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of the RECELL System Combined with Meshed Autograft for Reduction of Donor Skin Harvesting Contract $229,008.88 Clinical Trial Lourdes Castanon Surgery Avita Medical Americas, LLC 01/2021
A Phase 1/2 Study of ZN-c3 as a Single Agent in Combination with Talazoparib or Pembrolizumab in Patients with Solid Tumors Contract $138,409.52 Clinical Trial Pavani Chalasani Cancer Center Division K-Group Beta, Inc. 03/2020
A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are.... Contract $418,725.38 Clinical Trial Edward Gelmann Cancer Center Division Bristol-Myers Squibb 11/2020
SWOG NCORP Research Base Cooperative Agreement $54,000.00 Clinical Trial Daniel Persky Cancer Center Division Oregon Health and Science University 07/2020
A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With An Anti-PD1 Therapy Contract $220,879.50 Clinical Trial Montaser Shaheen Cancer Center Division Nanobiotix (France) 10/2020
Children, Adolescents and Their providers: the Narcolepsy Assessment Partnership (CATNAP) Contract $67,500.00 Clinical Trial Saif Mashaqi Medicine Pulse Infoframe US, LLC 04/2021
A Randomized, Double Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing... Contract $1,019,895.00 Clinical Trial Ranjit Kylathu Pediatrics Infant Bacterial Therapeutics AB (SWEDEN) 01/2021
A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Contract $128,059.00 Clinical Trial Ramachandra Sista COM Phx Internal Medicine BREATH Therapeutics Inc. 03/2020
A Multicenter Platform Evaluating Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults Contract $665,000.00 Clinical Trial Jarrod Mosier Dept of Emergency Medicine Social & Scientific Systems, Inc 12/2020
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of ... Contract $205,152.00 Clinical Trial Krisstina Gowin Cancer Center Division IQVIA RDS Inc. 11/2020
A Phase Ib/II Study of Leronlimab (PRO 140) Combined with Carboplatin in Patients with CCR5+ Metastatic Triple-Negative Breast Cancer (mTNBC) Contract $122,212.50 Clinical Trial Sima Ehsani Chimeh Cancer Center Division CytoDyn Inc. 10/2020
Efficacy of Fenofibrate for COVID-19: A Phase II Randomized Controlled Trial Grant $142,543.00 Clinical Trial Nancy Sweitzer Sarver Heart Center University of Pennsylvania 04/2021
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination with Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients with Contract $840,502.68 Clinical Trial Ricklie Julian Cancer Center Division Syneos Health 01/2021
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small... Contract $382,779.00 Clinical Trial Linda Garland Cancer Center Division Merck Sharp & Dohme Corp. 03/2020
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC) Contract $173,775.50 Clinical Trial Deepak Acharya Sarver Heart Center Windtree Therapeutics, Inc. 12/2020
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impa Contract $205,152.00 Clinical Trial Krisstina Gowin Cancer Center Division IQVIA RDS Inc. 11/2020
COG NCTN Network Group Operations Center Contract $750,000.00 Clinical Trial Holly Pariury Cancer Center Division Children's Hospital of Philadelphia 10/2020
Evaluating KODEX-EPD Electrophysiology Mapping During Cryoballoon Pulmonary Vein Isolation Contract $42,013.80 Clinical Trial Wilber Su COM Phx Internal Medicine Philips 04/2021
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult Contract $345,225.92 Clinical Trial Franz Rischard Medicine PhaseBio Pharmaceuticals, Inc. 01/2021
A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE) Contract $20,713.00 Clinical Trial Shona Dougherty Radiation Oncology University of Florida 03/2020
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patien Contract $406,077.84 Clinical Trial Setsuko Chambers Cancer Center Division GOG Foundation, Inc. 12/2020

Pages